Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 UCAR-NK Cells Combined with HSCT for B-Cell Malignancies
NCT05654038Phase 2Unknown
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-CD19 UCAR-NK cells in B-cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma. Status: unknown.
02
Drugs
anti-CD19 UCAR-NK cells
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT05654038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654038.